Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTOR
2024-516116-19-00Phase 2Authorised
- Sponsor
- University of Birmingham
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by University of Birmingham. Primary endpoint: Molecular event-free survival time (mEFS). Planned start Oct 2024; status: authorised.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-516116-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516116-19-00.